Clinical trial data and emerging strategies: HER2-positive breast cancer

Breast Cancer Res Treat. 2022 Jun;193(2):281-291. doi: 10.1007/s10549-022-06575-7. Epub 2022 Apr 9.


A deeper insight into tumor biology and HER2 signaling has led to the development of novel anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-positive breast cancer. The breast cancer immune microenvironment has emerged as a potential prognostic factor. Moreover, the host immune system not only seems to play a critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate treatment response to some HER2-targeted agents. Here, we review the latest evidence of the role of immunotherapy in HER2-positive breast cancer and present emerging strategies.

Keywords: Antibody-dependent cellular cytotoxicity; HER2-positive breast cancer; Immune checkpoints; Immunotherapy; Tumor immune microenvironment; Tumor-infiltrating lymphocytes.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Immunotherapy
  • Lymphocytes, Tumor-Infiltrating
  • Prognosis
  • Receptor, ErbB-2
  • Tumor Microenvironment


  • Antineoplastic Agents
  • Receptor, ErbB-2